Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ACER Acer Therapeutics (ACER) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Acer Therapeutics Stock (NASDAQ:ACER) 30 days 90 days 365 days Advanced Chart Ad Crypto 101 MediaThe #1 Coin for November 2024Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide… You can get access to the report by clicking here now… Get Acer Therapeutics alerts:Sign Up Key Stats Today's Range$0.66▼$0.8550-Day Range$0.66▼$0.9052-Week Range$0.55▼$4.56Volume574,600 shsAverage VolumeN/AMarket Capitalization$16.15 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAcer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. The company's pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-801 for the treatment of induced Vasomotor Symptoms, post-traumatic stress disorder, and prostate cancer; and OLPRUVA, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease. It has a license agreement with Sanofi to acquire worldwide rights to Osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist; an option agreement with Relief for the development, regulatory approval, and commercialization of OLPRUVA; and an agreement with Emory University to acquire the worldwide intellectual property rights to a family of patents and patent applications related to the use of neurokinin receptor antagonists in managing conditioned fear and treating anxiety disorders, including post-traumatic stress disorder. The company was incorporated in 1991 and is headquartered in Newton, Massachusetts.Read More… Receive ACER Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acer Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ACER Stock News HeadlinesGoogle Cloud to mandate Multi-Factor Authentication from 2025- ReportNovember 6, 2024 | msn.comVascular Ehlers-Danlos Syndrome Market on Track for Major Expansion by 2032, According to DelveInsight | Aytu BioPharma, Acer TherapeuticsNovember 5, 2024 | theglobeandmail.comURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.December 22, 2024 | Crypto Swap Profits (Ad)Global and Taiwan ICT Industry Research Report 2024: Market Performance, AI PC and AI Server Shipment Forecasts 2020-2024 & 2024-2028November 4, 2024 | finance.yahoo.comAcer Therapeutics Inc (OTC:ACER) Stock Quotes, Forecast and News SummaryAugust 16, 2024 | benzinga.comAnumana Appoints Harry S. Palmin as CFOMay 14, 2024 | tmcnet.comVehicle crashes into North Avenue restaurantMay 1, 2024 | msn.comArrest made following shots fired incident on Vann AvenueApril 30, 2024 | msn.comSee More Headlines ACER Stock Analysis - Frequently Asked Questions How were Acer Therapeutics' earnings last quarter? Acer Therapeutics Inc. (NASDAQ:ACER) announced its quarterly earnings data on Friday, November, 19th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.05. Does Acer Therapeutics have any subsidiaries? The following companies are subsidiaries of Acer Therapeutics: Opexa Therapeutics Inc.. What other stocks do shareholders of Acer Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Acer Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), CymaBay Therapeutics (CBAY), General Electric (GE), Meta Platforms (META), Adobe (ADBE) and Novo Nordisk A/S (NVO). Company Calendar Last Earnings11/19/2021Today12/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ACER CUSIPN/A CIK1069308 Webwww.acertx.com Phone(844) 902-6100Fax281-872-8585Employees30Year Founded2013Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$1.26 million Price / Sales12.81 Cash FlowN/A Price / Cash FlowN/A Book Value($1.05) per share Price / Book-0.63Miscellaneous Outstanding Shares24,460,000Free Float19,963,000Market Cap$16.15 million OptionableNot Optionable BetaN/A Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:ACER) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acer Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acer Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.